Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri

Dursun Çadırcı; Şenay Koçakoğlu

Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri

Öz

Çin’de başlayıp hızla yayılan yüzyılın ilk pandemisi tüm dünyayı etkisi altına aldı. Birinci basamak hekimlerinin en önemli görevleri arasında yer alan koruyucu sağlık hizmetlerinin önemi, bir kez daha gün yüzüne çıkmış oldu. COVID-19 enfeksiyonu ile mücadelede risk faktörlerinin ve risk gruplarının tanınması önemlidir. Korunma ve tedavilerin sağlanmasında yüksek riskli popülasyonların tanınması ve öncelenmesi, morbidite ve mortalite oranlarını düşürmek için gerekli stratejilerin belirlemesi, hayati önem taşımaktadır. Ayrıca korunma yöntemlerinin topluma yayılması, COVID-19 ile mücadelede başarının anahtarı olacaktır. Bu makalede koronavirus risk grupları ve korunma yöntemleri ele alınmıştır.

Anahtar Kelimeler

Kaynakça

1. World Health Organization WHO. Novel coronavirus (2019- nCoV) WHO Information Network for Epidemics 2020 [updated 31 January 2020; cited 2020 June 18]. Available from: https://www.who.int/docs/default-source/coronaviruse/riskc o m m s - u p d a t e s / u p d a t e - 4 - e p i - w i n - n c o v - 0.pdf?sfvrsn=4844408f_2.
2. Aktoz M, Altay H, Aslanger E, Atalar E, Atar İ, Aytekin V, et al. Türk Kardiyoloji Derneği Uzlaşı Raporu: COVID-19 Pandemisi ve Kardiyovasküler Hastalıklar Konusunda Bilinmesi Gerekenler. Turk Kardiyol Dern Ars. 2020;48(1):1-87.
3. World Health Organization WHO. WHO Coronavirus Disease (COVID-19) Dashboard 2020 [cited 2020 June 11]. Available from: https://covid19.who.int/.
4. World Health Organization WHO. Coronavirus disease (COVID- 19) Situation Report – 139 2020 [cited 2020 June 11]. Available from: https://www.who.int/docs/default-source/coronaviruse/ situation-reports/20200607-covid-19-sitrep- 139.pdf?sfvrsn=79dc6d08_2.
5. Beyazadam D, Alimoğlu O. Healthcare Workers Are Losing Their Lives in the Battle of Covid-19 All Over the Globe. Anadolu Kliniği Tıp Bilimleri Dergisi.25(Supplement 1):183-4.
6. Türkiye Bilimler Akademisi TÜBA. Covid-19 Pandemi Değerlendirme Raporu. Ankara, TURKEY; 2020. Report No.: 34.
7. Tan W, Zhao X, Ma X, Wang W, Niu P, Xu W, et al. A novel coronavirus genome identified in a cluster of pneumonia cases— Wuhan, China 2019− 2020. China CDC Weekly. 2020;2(4):61-2.
8. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology. 2020;94(7).

9. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nature medicine. 2020;26(4):450-2.
10. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. nature. 2020;579(7798):270-3.
11. McIntosh K. Coronavirus disease 2019 (COVID-19): Epidemiology, virology, and prevention: UpToDate, Inc. ; 2020 [updated June 15, 2020; cited 2020 June 18]. Available from: https://www.uptodate.com/contents/coronavirus-disease-2019- covid-19-epidemiology-virology-and-prevention.
12. Van Doremalen N, Bushmaker T, Morris D, Holbrook M, Gamble A, Williamson B. & Lloyd-Smith, JO (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV- 1. New England Journal of Medicine. 2020.
13. Centers for Disease Control and Prevention CDC. Coronavirus Disease 2019 (COVID-19)- How COVID-19 Spreads [updated 16 June 2020; cited 2020 June 18]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prevent-gettingsick/ how-covid-spreads.html.
14.World Health Organization WHO. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations: scientific brief, 27 March 2020. World Health Organization; 2020.
15.World Health Organization WHO. Coronavirus (Covid-19) Update 20- How it spreads 2020 [updated 27 March 2020; cited 2020 June 18]. Available from: https://www.who.int/docs/default- source/coronaviruse/risk-comms-updates/update-20- epi-win-covid-19.pdf?sfvrsn=5e0b2d74_2.
16.World Health Organization WHO. Coronavirus Symptoms 2020 [cited 2020 26 May]. Available from: https://www.who.int/health- topics/coronavirus#tab=tab_3.
17. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID- 19) infection: a systematic review and meta-analysis. International Journal of Infectious Diseases. 2020.
18. England. PH. COVID-19: infection prevention and control guidance: gov.UK 2020 [updated 21 May 2020; cited 2020 24 April]. Available from: https://assets.publishing.service.gov.uk /government/uploads/system/uploads/attachment_data/file/8866 68/COVID-19_Infection_prevention_and_control_guidance _complete.pdf.
19. Karaca B. Erişkin Yaş Grubunda COVID-19 Klinik Bulguları. Journal of Biotechnology and Strategic Health Research. 4:85-90.
20.World Health O. Clinical management of severe acute respiratory infection (􀀀􀀀SARI)􀀀􀀀 when COVID-19 disease is suspected: interim guidance, 13 March 2020. Geneva: World Health Organization; 2020 2020. Contract No.: WHO/2019- nCoV/clinical/2020.4.
21.McIntosh K. Coronavirus disease 2019 (COVID-19): Clinical features and diagnosis: UpToDate, Inc. ; 2020 [updated June 15, 2020; cited 2020 June 18]. Available from: https://www.uptodate.com/contents/coronavirus-disease-2019- covid-19-clinical-features-and-diagnosis?search=covid&topicRef= 127551&source=see_link.
22. T.C. Sağlık Bakanlığı HSGM. Covid-19 (SARS-CoV-2 Enfeksiyonu) Rehberi- Bilim Kurulu Çalışması 2020 [updated 14 April 2020; cited 2020 May 30]. Available from: https://covid19bilgi. saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf.
23. Jason Oke CH. Global Covid-19 Case Fatality Rates 2020 [updated 9th June 2020; cited 2020 June 18]. Available from: https://www.cebm.net/covid-19/global-covid-19-case-fatality- rates/.
24.Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239-42.
25. Smith KF, Dobson AP, McKenzie FE, Real LA, Smith DL, Wilson ML. Ecological theory to enhance infectious disease control and public health policy. Frontiers in Ecology and the Environment. 2005;3(1):29-37.
26. Lighter J, Phillips M, Hochman S. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission [published online April 9, 2020]. Clin Infect Dis.
27. Cao J, Tu W-J, Cheng W, Yu L, Liu Y-K, Hu X, et al. Clinical features and short-term outcomes of 102 patients with corona virus disease 2019 in Wuhan, China. Clinical Infectious Diseases. 2020.
28. COVID C, Team R. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343-6.
29. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed asymptomatic carrier transmission of COVID-19. Jama. 2020;323(14):1406-7.
30. Zhang J-j, Dong X, Cao Y-y, Yuan Y-d, Yang Y-b, Yan Y-q, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020.
31. Cai H. Sex difference and smoking predisposition in patients with COVID-19. The Lancet Respiratory Medicine. 2020;8(4):e20.
32. Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for cancer patients [published online ahead of print, 2020 Mar 3]. Lancet Oncol. 2020:30150-9.
33. Lewis T. Smoking or Vaping May Increase the Risk of Severe Coronavirus Infection. Scientific American. 2020;17.
34.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.
35. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi- Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID- 19 pandemic. Journal of the American College of Cardiology. 2020;75(18):2352-71.
36. Bornstein SR, Dalan R, Hopkins D, Mingrone G, Boehm BO. Endocrine and metabolic link to coronavirus infection. Nature Reviews Endocrinology. 2020;16(6):297-8.
37. Paul M Palevsky MR, MD, MSRaymond R Townsend, MD. Coronavirus disease 2019 (COVID-19): Issues related to kidney disease and hypertension: UpToDate, Inc.; 2020 [updated Jun 16, 2020; cited 2020 June 18]. Available from: https://www.uptodate. com/contents/coronavirus-disease-2019-covid-19-issues- related-to-kidney-disease-and-hypertension.
38. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. International urology and nephrology. 2020:1-2.
39. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. New England Journal of Medicine. 2020.
40.Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin– angiotensin–aldosterone system blockers and the risk of Covid-19. New England Journal of Medicine. 2020.
41. Özşeker ZF. Astım ve COVID-19. ğer: Göğüs Hastalıkları Uzmanlarının Bilmesi Gerekenler’başlıklı ek sayısında derlemeyi.89. 42. Guan W-J, Liang W-H, Zhao Y, Liang H-R, Chen Z-S, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID- 19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547.
43. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
44. He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID- 19 in persons with haematological cancers. Leukemia. 2020:1-9.
45. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020;21(3):335-7.
46. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID- 19 in Wuhan, China: a retrospective cohort study. The lancet. 2020.
47. You B, Ravaud A, Canivet A, Ganem G, Giraud P, Guimbaud R, et al. The official French guidelines to protect patients with cancer against SARS-CoV-2 infection. The Lancet Oncology. 2020;21(5):619-21.
48. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. bmj. 2020;369.
49. Guo L, Wei D, WU Y, ZHOU M, ZHANG X, Li Q, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Frontiers in Microbiology. 2019;10:2752.
50. Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID- 19) during the early outbreak period: a scoping review. Infectious diseases of poverty. 2020;9(1):1-12.
51. T.C. Sağlık Bakanlığı HSGM. Covid-19 (SARS-CoV-2 Enfeksiyonu) Enfeksiyon Kontrolü ve İzolasyon 2020 [updated 01 Haziran 2020; cited 2020 10 Haziran]. Available from: https://covid19bilgi.saglik.gov.tr/depo/rehberler/covid-19- rehberi/COVID-19_REHBERI_ENFEKSIYON_KONTROLU_ VE_IZOLASYON.pdf.
52. Hatipoğlu N. The" New" Problem of Humanity: New Coronavirus (2019-nCoV/COVID-19) Disease. Medical Journal of Bakirkoy. 2020;16(1).
53.Wenhong C, Yibin C, Hui C, Chunhua C, Gangqiang D, Xueping D et al. Handbook on COVID-19 Infection Prevention and Control in Communities. Bureau of Disease Prevention and Control of National Health Commission of People’s Republic
of China 2020.[cited: 2020 June 11]. Available from:: https://www.ipcrg.org/sites/ipcrg/files/content/attachments/ 2020-04-30/Handbook%20on%20COVID-19%20Infection% 20Prevention%20and%20Control%20in%20Communities. pdf

Ayrıntılar

Birincil Dil

Türkçe

Konular

İç Hastalıkları

Bölüm

Derleme

Yazarlar

Dursun Çadırcı ^* Bu kişi benim
Türkiye

Şenay Koçakoğlu Bu kişi benim
Türkiye

Yayımlanma Tarihi

1 Nisan 2020

Gönderilme Tarihi

23 Mart 2020

Kabul Tarihi

11 Nisan 2020

Yayımlandığı Sayı

Yıl 2020 Cilt: 12 Sayı: 2

IZ

https://izlik.org/JA42JZ65YE

Kaynak Göster

RIS / Bibtex

APA

Çadırcı, D., & Koçakoğlu, Ş. (2020). Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri. Klinik Tıp Aile Hekimliği, 12(2), 62-68. https://izlik.org/JA42JZ65YE

AMA

1.Çadırcı D, Koçakoğlu Ş. Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri. Aile Hekimliği. 2020;12(2):62-68. https://izlik.org/JA42JZ65YE

Chicago

Çadırcı, Dursun, ve Şenay Koçakoğlu. 2020. “Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri”. Klinik Tıp Aile Hekimliği 12 (2): 62-68. https://izlik.org/JA42JZ65YE.

EndNote

Çadırcı D, Koçakoğlu Ş (01 Nisan 2020) Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri. Klinik Tıp Aile Hekimliği 12 2 62–68.

IEEE

[1]D. Çadırcı ve Ş. Koçakoğlu, “Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri”, Aile Hekimliği, c. 12, sy 2, ss. 62–68, Nis. 2020, [çevrimiçi]. Erişim adresi: https://izlik.org/JA42JZ65YE

ISNAD

Çadırcı, Dursun - Koçakoğlu, Şenay. “Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri”. Klinik Tıp Aile Hekimliği 12/2 (01 Nisan 2020): 62-68. https://izlik.org/JA42JZ65YE.

JAMA

1.Çadırcı D, Koçakoğlu Ş. Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri. Aile Hekimliği. 2020;12:62–68.

MLA

Çadırcı, Dursun, ve Şenay Koçakoğlu. “Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri”. Klinik Tıp Aile Hekimliği, c. 12, sy 2, Nisan 2020, ss. 62-68, https://izlik.org/JA42JZ65YE.

Vancouver

1.Dursun Çadırcı, Şenay Koçakoğlu. Koronavirüs Pandemisinde Risk Grupları ve Korunma Yöntemleri. Aile Hekimliği [Internet]. 01 Nisan 2020;12(2):62-8. Erişim adresi: https://izlik.org/JA42JZ65YE